Managers / Q1 2026
DIADEMA PARTNERS LP
CIK 0002026172 · 2140 HEADQUARTERS PLAZA, EAST TOWER, 2ND FLOOR, MORRISTOWN, NJ, 07960 · 917-513-8539
Reported Value
$588M
Q1 2026
Positions
144
Filings on Record
6
2019–present window
Filed
May 15, 2026
original filing
Summary
Diadema Partners Lp reported $588M in U.S.-listed holdings across 144 positions for Q1 2026.
Its largest position, Bridgebio Pharma, represents 3.2% of the portfolio.
Compared with Q4 2025, the fund opened 44 new positions and exited 52.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
Holdings — Q1 2026
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $588M | 144 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $581M | 145 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $391M | 130 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $328M | 96 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $383M | 102 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $233M | 107 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.